Frank A. Sinicrope, MD

Frank A. Sinicrope, MD, previews 2 colorectal cancer studies to watch at the 2026 ESMO Congress, including adjuvant intensification and AZUR-1.

Frank A. Sinicrope, MD, discusses the FDA approval of the ATOMIC trial regimen for patients with stage III dMMR colon cancer.

Frank A. Sinicrope, MD, discuses the implications of data with atezolizumab plus adjuvant mFOLFOX6 for the management of stage III, dMMR colon cancer.

Frank A. Sinicrope, MD, discuses the efficacy and safety of atezolizumab plus mFOLFOX6 in patients with stage III dMMR colon cancer

Frank A. Sinicrope, MD, medical oncologist, Departments of Gastroenterology and Hepatology and Oncology, Mayo Clinic, discusses patients with metastatic colorectal cancer (mCRC) who are mismatch repair-deficient.